Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05932680
Other study ID # UPCC 08423
Secondary ID IRB 853459
Status Recruiting
Phase Phase 2
First received
Last updated
Start date July 5, 2023
Est. completion date January 2027

Study information

Verified date July 2023
Source Abramson Cancer Center at Penn Medicine
Contact Stacey Pundock
Phone 856-689-1904
Email Stacy.Pundock@pennmedicine.upenn.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-arm, non-inferiority study in which patients who have achieved a very good partial response (VGPR) or better, according to International Myeloma Working Group (IMWG) response criteria, following 6 to 9 months of treatment with teclistamab, a B-cell maturation antigen (BCMA)-directed T-cell engager (anti-BCMAxCD3 bispecific antibody), will be offered monitored drug discontinuation. Teclistamab is typically dosed on a regular schedule (every 1-4 weeks) indefinitely until disease progression ("continuous therapy"). Here, a limited-duration regimen will be studied in which patients achieving ≥VGPR after 6-9 months of standard teclistamab dosing will discontinue therapy and resume if laboratory or clinical parameters suggest early disease progression ("limited-duration therapy"). Patients will enter the clinical trial protocol after completing 6-9 months of standard teclistamab monotherapy and achieving ≥VGPR. The study's hypothesis is that the failure probability six months after stopping teclistamab in this patient population will be non-inferior compared to that of historical controls treated with continuous therapy. Reducing drug exposure may be beneficial by reducing risk of infection and reducing anti-BCMA selective pressure toward generation of BCMA-negative relapses. Analysis of minimal residual disease (MRD), tumor features, and bone marrow microenvironment parameters, which will be pursued as exploratory correlative analyses in this study, may identify factors that predict durable response to limited-duration therapy and thereby enable more precise selection of patients likely to benefit from this approach. A subset of patients will be enrolled on a biomarker study for analysis of these exploratory endpoints.


Recruitment information / eligibility

Status Recruiting
Enrollment 75
Est. completion date January 2027
Est. primary completion date June 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participants must be age =18 and able to give written, informed consent. - Participants must have initiated teclistamab (first full dose) 6-9 months prior to enrollment and received an average teclistamab dose of at least 1.5 mg/kg/month since the date of the first 1.5 mg/kg dose. - Participants must have received a teclistamab dose within 4 weeks prior to enrollment. - Participants must have had measurable disease according to IMWG criteria within 1 month prior to teclistamab initiation or first full teclistamab dose - Participants must have achieved a confirmed VGPR or better to teclistamab therapy at any assessment prior to enrollment and have ongoing response (i.e., no disease progression) at time of enrollment per IMWG consensus criteria (Appendix 14.3). - Prior to initiating teclistamab, participants must have received therapy with a proteasome inhibitor, thalidomide analog (lenalidomide or pomalidomide), and an anti-CD38 antibody and meet one of the following criteria: 1. =3 prior lines of therapy (with lines-of-therapy delineated according to IWMG guidelines) 2. Refractory to both a proteasome inhibitor and a thalidomide analog. - Participants must have had an ECOG performance status of 0-2 at time of teclistamab initiation; in addition, ECOG performance status must be 0-1 at time of enrollment. - Participants must not have known diagnoses of systemic amyloidosis or POEMS syndrome.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Off Drug Surveillance
After stopping teclistamab, participants will be monitored monthly by standard serum paraprotein studies for disease progression. Participants will resume teclistamab at time of disease progression. After Teclistamab therapy re-initiation on-study, monthly response assessments and data for other study endpoints will be obtained. All participants will undergo peripheral blood collection for correlative research studies at baseline and every two months on-study. Participants who enroll on the biomarker sub-study will undergo bone marrow examination and peripheral blood collection for correlative studies at study entry, at time of disease progression and at six months from enrollment.

Locations

Country Name City State
United States Abramson Cancer Center at University of Pennsylvania Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Abramson Cancer Center at Penn Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Failure free at six months following teclistamab discontinuation Failure-free survival is defined as the rate of evaluable individuals who have not experienced any of the following predefined failure events within 6 months of discontinuing teclistamab. Failure is defined as earliest occurrence of any of the following: Participants who progress by IMWG criteria after discontinuing teclistamab, failure to achieve at least minimal response within 90 days after reinitiating teclistamab or failure to resume teclistamab within 90 days of IMWG-defined disease progression. Participants who reinitiate teclistamab due to rise in disease markers before IMWG criteria for disease progression are met, disease progression by IMWG criteria after reinitiation of teclistamab. Initiation of non-teclistamab systemic multiple myeloma therapy. Failure date will be defined as the date of initiating subsequent therapy. Death due to complications of multiple myeloma, teclistamab therapy, or infection Six months after teclistamab discontinuation
Secondary Time to progression and progression-free survival Time-to-progression and progression-free survival by IMWG criteria from time of teclistamab discontinuation, using the best response to initial teclistamab course as the baseline for scoring disease progression. Two years after teclistamab discontinuation.
Secondary Time-to-treatment failure Time-to-treatment failure as defined in the primary endpoint Two years after teclistamab discontinuation
Secondary Re-initiation rate Proportion of subjects who re-initiate teclistamab within six months following discontinuation Six months after teclistamab discontinuation
Secondary Rate of response to teclistamab re-initiation Among subjects with IMWG-defined measurable disease at time of teclistamab re-initiation, overall response rate (PR or better) and clinical benefit rate (minimal response or better) to teclistamab upon re-initiating therapy. Two years after teclistamab discontinuation
Secondary Rate of infectious complications Frequency of infectious complications from time of teclistamab discontinuation. 12 months after teclistamab discontinuation
Secondary Rate and type of clinical complications of progressive disease Frequency of the type and rate of clinical complications of progressive disease (e.g., new osteolytic lesions) from time of teclistamab discontinuation through 6 months post-discontinuation. Six months after teclistamab discontinuation
Secondary Quality of life Health-related quality of life (HRQoL) as measured by Functional Assessment of Cancer Therapy - Multiple Myeloma (FACT-MM) questionnaire score at enrollment and monthly post-enrollment assessments. The higher the score, the better the quality of life. Two scores will be derived - FACT-MM Trial Outcome Index (TOI) (range: 0-112) and FACT-MM total score (range: 0-164). Two years after teclistamab discontinuation
Secondary Mean percent change in peripheral blood studies Mean percent change in peripheral blood cell counts, immunoglobulin levels, and T cell counts (total and CD4/CD8 subsets) from the time of enrollment through teclistamab resumption and through the end-of-study. Two years after teclistamab discontinuation
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06205823 - Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM
Recruiting NCT04782687 - Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma Phase 2
Active, not recruiting NCT05889221 - Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma N/A
Recruiting NCT03891914 - Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma Phase 3
Not yet recruiting NCT05944783 - Bioequivalence Studies of Dasatinib 100 mg Phase 4
Recruiting NCT04268199 - A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment Phase 2
Not yet recruiting NCT06133426 - Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients N/A
Completed NCT05887206 - Corneal Toxicity in Patients Treated by Belantamab Mafodotin
Completed NCT04065789 - Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients Phase 2
Active, not recruiting NCT03089411 - Collection of Additional Data Followed the Study IFM 2013-04 N/A
Completed NCT04436029 - Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy Phase 2
Not yet recruiting NCT04364724 - CTFEA Myeloma Study
Not yet recruiting NCT06418750 - Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study N/A
Completed NCT04236063 - Rehabilitation Needs of the Malaysian Haematological Cancer Survivors
Terminated NCT04242121 - The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood
Not yet recruiting NCT03607643 - A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies Phase 1/Phase 2
Recruiting NCT05651932 - A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma Phase 1
Not yet recruiting NCT06245629 - Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
Recruiting NCT03992170 - Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive Phase 2
Terminated NCT04843579 - Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients Phase 2